Cargando…

The respiratory microbiome associated with chronic obstructive pulmonary disease comorbidity in non‐small cell lung cancer

BACKGROUND: Research has shown that some microbiomes are linked to cancer. Hence, we hypothesize that alterations in the respiratory microbiome might be associated with lung cancer. METHODS: Through droplet digital polymerase chain reaction analysis, we investigated the abundance of Acidovorax in su...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shimizu, Masamitsu, Miyanaga, Akihiko, Seike, Masahiro, Matsuda, Kuniko, Matsumoto, Masaru, Noro, Rintaro, Fujita, Kazue, Mano, Yoko, Furuya, Nobuhiko, Kubota, Kaoru, Gemma, Akihiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250845/ https://www.ncbi.nlm.nih.gov/pubmed/35580613 http://dx.doi.org/10.1111/1759-7714.14463

Ejemplares similares

miR-200/ZEB axis regulates sensitivity to nintedanib in non-small cell lung cancer cells
por: NISHIJIMA, NOBUHIKO, et al.
Publicado: (2016)

Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancer
por: Matsumoto, Masaru, et al.
Publicado: (2015)

Inhibitors of ABCB1 and ABCG2 overcame resistance to topoisomerase inhibitors in small cell lung cancer
por: Omori, Miwako, et al.
Publicado: (2022)

Osimertinib early dose reduction as a risk to brain metastasis control in EGFR‐mutant non‐small cell lung cancer
por: Tozuka, Takehiro, et al.
Publicado: (2023)

Effective Crizotinib schedule for an elderly patient with ALK rearranged non-small-cell lung cancer: a case report
por: Fukuizumi, Aya, et al.
Publicado: (2015)

Efficacy with Trastuzumab Deruxtecan for Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutation in a Patient with a Poor Performance Status: A Case Report
por: Kato, Yuki, et al.
Publicado: (2021)

MET FISH-positive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutation
por: Noro, Rintaro, et al.
Publicado: (2015)

Bevacizumab plus chemotherapy in nonsquamous non‐small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B
por: Noro, Rintaro, et al.
Publicado: (2020)

Successful Treatment with Short-Term Steroid Against Severe Hepatitis Confirmed by Liver Biopsy in a Patient with Advanced Squamous-Cell Lung Cancer Receiving a Combination of Pembrolizumab, Carboplatin, and Nab-Paclitaxel: A Case Report
por: Hayashi, Anna, et al.
Publicado: (2022)

Overcoming drug-tolerant cancer cell subpopulations showing AXL activation and epithelial–mesenchymal transition is critical in conquering ALK-positive lung cancer
por: Nakamichi, Shinji, et al.
Publicado: (2018)

Alectinib-Induced Severe Hemolytic Anemia in a Patient with ALK-Positive Non-Small Cell Lung Cancer: A Case Report
por: Misawa, Kazuhito, et al.
Publicado: (2023)

Long Non-Coding RNA CRNDE Is Involved in Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant Lung Cancer via eIF4A3/MUC1/EGFR Signaling
por: Takahashi, Satoshi, et al.
Publicado: (2021)

CADM1 and SPC25 Gene Mutations in Lung Cancer Patients With Idiopathic Pulmonary Fibrosis
por: Fukuizumi, Aya, et al.
Publicado: (2021)

Exosome‐derived miR‐210 involved in resistance to osimertinib and epithelial–mesenchymal transition in EGFR mutant non‐small cell lung cancer cells
por: Hisakane, Kakeru, et al.
Publicado: (2021)

Successful Treatment with Afatinib after Osimertinib-induced Interstitial Lung Disease in a Patient with EGFR-mutant Non-small-cell Lung Cancer
por: Nishima, Shunichi, et al.
Publicado: (2020)

Remarkable Clinical Response of ALK-Rearranged/TP53-Mutant Lung Adenocarcinoma with Liver Metastasis to Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel After ALK Inhibitors: A Case Report
por: Iso, Hirokazu, et al.
Publicado: (2023)

Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer
por: Takahashi, Akiko, et al.
Publicado: (2018)

Immune checkpoint inhibitor‐associated interstitial lung diseases correlate with better prognosis in patients with advanced non‐small‐cell lung cancer
por: Sugano, Teppei, et al.
Publicado: (2020)

Carboplatin plus nanoparticle albumin-bound paclitaxel for the treatment of thymic carcinoma
por: Takahashi, Akiko, et al.
Publicado: (2022)

Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation
por: Noro, Rintaro, et al.
Publicado: (2006)

Anticancer drug clustering in lung cancer based on gene expression profiles and sensitivity database
por: Gemma, Akihiko, et al.
Publicado: (2006)

Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4–ALK-rearranged non–small–cell lung cancer harbored coexisting EGFR mutation
por: Miyanaga, Akihiko, et al.
Publicado: (2013)

Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report
por: Sugano, Teppei, et al.
Publicado: (2019)

Acute respiratory failure due to Aspergillus niger infection with acute fibrinous and organazing pneumonia: A case report
por: Okamura, Ken, et al.
Publicado: (2022)

A case of interstitial lung disease with alveolar hemorrhage induced by pembrolizumab
por: Sugano, Teppei, et al.
Publicado: (2018)

Standard versus low‐dose nab‐paclitaxel in previously treated patients with advanced non‐small cell lung cancer: A randomized phase II trial (JMTO LC14‐01)
por: Takeuchi, Susumu, et al.
Publicado: (2023)

Prognostic significance of PIK3CA and SOX2 in Asian patients with lung squamous cell carcinoma
por: IIJIMA, YOSHIHITO, et al.
Publicado: (2014)

EML4-ALK induces cellular senescence in mortal normal human cells and promotes anchorage-independent growth in hTERT-transduced normal human cells
por: Miyanaga, Akihiko, et al.
Publicado: (2021)

Pembrolizumab-induced agranulocytosis in a pulmonary pleomorphic carcinoma patient who developed interstitial lung disease and ocular myasthenia gravis
por: Tozuka, Takehiro, et al.
Publicado: (2018)

MiR-23a regulates TGF-β-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cells
por: CAO, MENGRU, et al.
Publicado: (2012)

Oral rehydration solution (OS-1) as a substitute of intravenous hydration after cisplatin administration in patients with lung cancer: a prospective multicenter trial
por: Horinouchi, Hidehito, et al.
Publicado: (2018)

Predictive Impact of Diffuse Positivity for TTF-1 Expression in Patients Treated With Platinum-Doublet Chemotherapy Plus Immune Checkpoint Inhibitors for Advanced Nonsquamous NSCLC
por: Terashima, Yuto, et al.
Publicado: (2023)

Efficacy of triple antiemetic therapy (palonosetron, dexamethasone, aprepitant) for chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based, moderately emetogenic chemotherapy
por: Miya, Toshimichi, et al.
Publicado: (2016)

Resolution of bleomycin-induced murine pulmonary fibrosis via a splenic lymphocyte subpopulation
por: Kamio, Koichiro, et al.
Publicado: (2018)

Pembrolizumab and salvage chemotherapy in EGFR T790M-positive non-small-cell lung cancer with high PD-L1 expression
por: Tozuka, Takehiro, et al.
Publicado: (2018)

Pulmonary manifestation of inflammatory bowel disease: Two case reports
por: Suzuki, Ayana, et al.
Publicado: (2023)

Benefits from Adjuvant Chemotherapy in Patients with Resected Non-Small Cell Lung Cancer: Possibility of Stratification by Gene Amplification of ACTN4 According to Evaluation of Metastatic Ability
por: Tozuka, Takehiro, et al.
Publicado: (2022)

Synergistic effect of targeting dishevelled-3 and the epidermal growth factor receptor-tyrosine kinase inhibitor on mesothelioma cells in vitro
por: Moriyama, Gaku, et al.
Publicado: (2018)

Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis
por: Inomata, Minoru, et al.
Publicado: (2014)

Alpha‐actinin‐4 (ACTN4) gene amplification is a predictive biomarker for adjuvant chemotherapy with tegafur/uracil in stage I lung adenocarcinomas
por: Noro, Rintaro, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mmni781s3j6dq335151b0ce5ct